Study start date
- Patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care therapy or are ineligible to receive such therapy.
Patients with advanced (metastatic or unresectable) KRAS G12C mutant non-small cell lung cancer who have received platinum-based chemotherapy regimen and immune checkpoint inhibitor therapy, unless patient was ineligible to receive such therapyPatients with advanced (metastatic or unresectable) KRAS G12C mutant colorectal cancer who have received fluropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, unless patient was ineligible to such therapy.
ECOG performance status of 0 or 1.Patients must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines.
Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutationsPrior treatment with a KRAS G12C inhibitor is excluded for patients in a subset of groups in Phase II. Active brain metastases, including symptomatic brain metastases or known leptomeningeal disease Clinically significant cardiac disease or risk factors at screening Insufficient bone marrow, hepatic or renal function at screening Other protocol-defined inclusion/exclusion criteria may apply